121 related articles for article (PubMed ID: 1422313)
1. Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD).
Cassinelli HR; Mautalen CA; Heinrich JJ; Miglietta A; Bergada C
Bone Miner; 1992 Nov; 19(2):175-84. PubMed ID: 1422313
[TBL] [Abstract][Full Text] [Related]
2. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
Vega E; Gonzalez D; Ghiringhelli G; Mautalen C
J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
[TBL] [Abstract][Full Text] [Related]
3. Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy.
Tau C; Mautalen C; Casco C; Alvarez V; Rubinstein M
Bone; 2004 Jul; 35(1):210-6. PubMed ID: 15207759
[TBL] [Abstract][Full Text] [Related]
4. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
[TBL] [Abstract][Full Text] [Related]
6. Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion.
Landman JO; Papapoulos SE
Osteoporos Int; 1995 Mar; 5(2):93-6. PubMed ID: 7599454
[TBL] [Abstract][Full Text] [Related]
7. Paget's disease of bone: five regimens of pamidronate treatment.
Pepersack T; Karmali R; Gillet C; François D; Fuss M
Clin Rheumatol; 1994 Mar; 13(1):39-44. PubMed ID: 8187442
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.
Heynen G; Delwaide P; Bijvoet OL; Franchimont P
Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650
[No Abstract] [Full Text] [Related]
9. Single-day intravenous pamidronate in Paget's disease.
Hooper MJ; Clifton-Bligh P; Marel GM; Lang FV; Tancred J; McDowall D; Forman L
Semin Arthritis Rheum; 1994 Feb; 23(4):276-7. PubMed ID: 8009255
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
11. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
[TBL] [Abstract][Full Text] [Related]
12. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
[TBL] [Abstract][Full Text] [Related]
13. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of Paget's disease with bisphosphonate pamidronate (AHPrBP, formerly APD)].
Scharla SH; Grauer A; Ziegler R
Klin Wochenschr; 1991 Jan; 69(1):25-30. PubMed ID: 2016845
[TBL] [Abstract][Full Text] [Related]
15. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium.
Stewart GO; Gutteridge DH; Price RI; Ward L; Retallack RW; Prince RL; Stuckey BG; Kent GN; Bhagat CI; Dhaliwal SS
Bone; 1999 Feb; 24(2):139-44. PubMed ID: 9951784
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of pamidronate in patients with metastatic bone disease.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
[TBL] [Abstract][Full Text] [Related]
18. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
19. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
Cantrill JA; Buckler HM; Anderson DC
Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665
[TBL] [Abstract][Full Text] [Related]
20. [Moderate Paget's disease treated with pamidronate (APD): experience in 43 patients with a single 60 mg infusion of varying duration of 1-to-24 hours].
Thiébaud D; Portmann L; Burckhardt P
Schweiz Med Wochenschr; 1992 Dec; 122(49):1889-94. PubMed ID: 1462150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
